Infliximab for ulcerative colitis in children and adolescents

Journal of Clinical Gastroenterology

Volumn 42, Issue 8, 2008, Pages 875-879

  McGinnis, Jean K ^a,b,c   Murray, Karen F ^a  

^a Landstuhl Regional Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Inflammatory bowel disease; Infliximab; Pediatrics; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; CYCLOSPORIN; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; METRONIDAZOLE; SALAZOSULFAPYRIDINE; STEROID; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; CELLULITIS; CHILD; CLINICAL ARTICLE; COLON RESECTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; DRUG RESISTANCE; HOSPITAL; METHODOLOGY; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HOSPITALS, PEDIATRIC; HUMANS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 54549088748     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181354417     Document Type: Article

References (25)

1. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999; 149:916-924.
2. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161-1168.
3. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
4. Pinchbeck BR, Kirdeikis J, Thomson AB. Inflammatory bowel disease in northern Alberta: an epidemiologic study. J Clin Gastroenterol. 1988;10:505-515.
5. Hyams JS, Davis P, Grancher K, et al. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996;129:81-88.
6. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146.
7. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
8. Kugathaasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
9. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001;35:823-828.
10. Hyams J, Crandall W, Kugasthasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132: 863-873.
11. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
12. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301.
13. Eidelwin AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213-218.
14. Russel GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004;39:166-170.
15. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;4947:1041-1048.
16. Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002;34: 631-634.
17. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001;7(supp 1):S30-S33.
18. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2273-2281.
19. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003;18:175-181.
20. Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001;113:930-933.
21. Kohn A, Prantera C, Pera A, et al. Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002;34:626-630.
22. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577-2584.
23. Probert CSJ, Hearing S, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut. 2003;52:998-1002.
24. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88.
25. Meinzer U, Idestrom M, Alberti C, et al. Ileal involvement is age dependent in pediatric Crohn's disease. Inflamm Bowel Dis. 2005;11:639-644.